Appili appoints Gelhaus, Baran as Directors to support ATi-1701 program

Appili Therapeutics has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, which is classified by the U.S. National Institutes of Health as a Category A pathogen and top-priority biothreat. Dr. Gelhaus brings over 20 years of infectious disease and animal model research experience to the role, with an emphasis on tularemia research. Arthur Baran brings to Appili more than 22 years of experience in global product manufacturing operations, drug product development team leadership, program management, business development, manufacturing site leadership and quality assurance.